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ABSTRACT: Friedreich’s ataxia (FRDA) is an autosomal
recessive neuro- and cardiodegenerative disorder for which
there are no proven eﬀective treatments. FRDA is caused by
decreased expression and/or function of the mitochondrial
protein frataxin. Here, we report ﬁndings that frataxin is
degraded via the ubiquitin−proteasomal pathway and that it is
ubiquitinated at residue K147 in Calu-6 cells. A theoretical
model of the frataxin-K147/Ub complex, constructed by
combining bioinformatics interface predictions with informa-
tion-driven docking, revealed a hitherto unnoticed, potential
ubiquitin-binding domain in frataxin. Through structure-based
virtual screening and cell-based assays, we discovered a novel
small molecule (compound (+)-11) able to prevent frataxin ubiquitination and degradation. (+)-11 was synthesized and tested
for speciﬁc binding to frataxin by an UF-LC/MS based ligand-binding assay. Follow-up scaﬀold-based searches resulted in the
identiﬁcation of a lead series with micromolar activity in disrupting the frataxin/Ub interaction. This study also suggests that
frataxin could be a potential target for FRDA drug development.
■ INTRODUCTION
Friedreich’s ataxia (FRDA) is an inherited recessive neuro-
degenerative disorder caused by a partial reduction in levels of
the mitochondrial protein frataxin,1,2 which controls the iron
homeostasis. FRDA is the most common inherited form of
ataxia with an incidence estimated between 1:30000 to 1:50000
in the U.S. and Europe.3−5 The disease is characterized by a
progressive neuropathy aﬀecting the central and peripheral
nervous systems,6,7 causing death of primary sensory neurons of
the dorsal root ganglia and a variable picture of accompanying
neurological symptoms.4 These symptoms tend to appear by
the age of 20 in the majority of patients, who are typically
normal at birth and during early childhood, although the
disease onset is highly variable and can be incomplete and/or
delayed for reasons yet to be described.8 FRDA is caused, in the
majority of cases, by an abnormal GAA repeat expansion in the
ﬁrst intron of the human FRDA gene,2 which inhibits transcription,9
leading in turn to multiple enzyme deﬁcits, mitochondrial
dysfunction, and oxidative damage.10,11 At present there is no
eﬀective pharmacological treatment available to slow the progression
of the disease.
Frataxin is encoded in the nucleus and synthesized in the
cytoplasm as a precursor polypeptide (frataxin1−210) that is
transported to the mitochondrial matrix and proteolytically
cleaved to the mature form (frataxin81−210)12,13 via a processing
intermediate (frataxin42−210).14,15 Maturation of the frataxin
precursor occurs within the mitochondrial matrix, and no other
intramitochondrial post-translational modiﬁcations have been
identiﬁed. Recently, a pool of mature frataxin was detected in
the cytoplasm of several cell types of human origin16−18 where
it participates in numerous biological functions.16,17,19 More
recent ﬁndings have shown the direct regulation of frataxin
precursor and mature accumulation through the ubiquitin−
proteasome system (UPS).20 Thus, small-molecule inhibitors
that promote frataxin stabilization are desirable and could
potentially have therapeutic value.
Here we report the discovery, synthesis, and characterization
of a small molecule (compound (+)-11) able to prevent the
frataxin ubiquitination and degradation and promote the
accumulation of cellular frataxin. To reach this goal, we built
a computational model of the frataxin/Ub interaction, using
HADDOCK (high-ambiguity-driven docking),21 a software of
wide use in structural biology for protein−protein docking.22
The putative frataxin Ub-binding domain was chosen for in
silico targeting in a multistep structure-based virtual screening
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approach using the National Cancer Institute (NCI) Open
Database. The most active compound (±)-11 was synthesized by
a new microwave-assisted procedure, and the resolution of its
enantiomers was put forward by a salt crystallization technique.
Only the (+)-isomer was active in accumulating both precursor
and mature frataxin in human lung adenocarcinoma (Calu-6) cells.
The binding aﬃnity of (+)-11 toward frataxin was proved through
an ultraﬁltration liquid chromatography/mass spectrometry (UF-
LC/MS) based ligand-binding assay.
■ RESULTS AND DISCUSSION
Frataxin Stability Is Controlled by the UPS in Calu-6
Cells. Previous results showed that proteasomal degradation of
both precursor and mature frataxin in human embryonic kidney
293 (HEK-293) cells is mediated by a Ub-dependent mechanism
and that K147 is the critical residue responsible for frataxin
ubiquitination.20 To validate these ﬁndings, we repeated these
experiments in Calu-6 cells and analyzed frataxin turnover in the
presence and absence of proteasome inhibition. Calu-6 cells, an
anaplastic carcinoma of lung origin, were chosen as a model
system in this study because they are well characterized, provide a
reasonably high transfection eﬃciency, and express elevated levels
of frataxin. Calu-6 cells were transiently transfected with a
construct expressing frataxin fused to His tag, and 32 h after
transfection cells were treated for 18 h with either 10 μM
reversible proteasome inhibitor MG132 (N-carbobenzoxyl-L-
leucinyl-L-leucinyl-L-leucinal) or 10 μM bortezomib, a peptide
boronic acid proteasome inhibitor. Proteins from cell lysates were
then analyzed by SDS−PAGE and Western blotting. As shown in
Figure 1, the addition of the reversible proteasome inhibitor
MG132 and bortezomib was found to cause a strong increase in
frataxin precursor compared to untreated samples.
In order to verify whether the frataxin precursor is targeted to
proteasomal degradation by Ub labeling, we went on to perform an
immunoprecipitation assay. Calu-6 cells were transiently co-transfected
with plasmids expressing both frataxin and Ub fused to His tag
(6-histidine) and HA tag (hemagglutinin), respectively. At 24 h
after the transfection, cells were treated with 10 μM MG132 for
18 h. Frataxin was then speciﬁcally immunoprecipitated from
untransfected and transfected cells using anti-frataxin, and the
resulting frataxin immunocomplexes were analyzed by SDS−
PAGE and Western blotting with antibodies against Ub. As
shown in Figure 2, both frataxin and the monoUb-tagged
precursor of frataxin accumulate by MG132 treatment. Interestingly,
the detection of a ladder of high molecular weight species char-
acteristic of polyubiquitinated proteins suggested that frataxin is also
polyubiquitinated.
To conﬁrm that K147 is really the ubiquitination site of frataxin,
we altered this residue to R by site-directed mutagenesis and
compared the ability of the resulting mutant (His-K147R) to bind
to glutathione S-transferase (GST) fused Ub (GST-monoUb)
with that of the frataxin wild-type. Calu-6 cells were transiently
transfected with the plasmid encoding either His-frataxin or the
mutant His-K147R. At 24 h after the transfection, cells were treated
with MG132 and lysed. His-tagged proteins were then tested for
their ability to bind immobilized GST-tagged Ub protein. The
puriﬁed GST and GST-monoUb were immobilized using
glutathione (GSH) Sepharose beads and incubated with cell
lysates containing the recombinant His-frataxin or the mutant His-
K147R. After binding, the proteins were eluted and analyzed by
Western blotting with antibodies against the-His epitope. Figure 3
shows that the signal for frataxin was present in the pull-down
sample containing the wilde-type frataxin but not in that of
Figure 1. Eﬀect of MG132 and bortezomib on the stability of human
frataxin. Western blot analysis with the indicated antibodies of protein
extracts from Calu-6 cells untransfected or transfected with His-
frataxin and untreated or treated with MG132 (a) or bortezomib (b)
for 18 h. The levels of proteins were quantiﬁed by PhosphorImager
(Bio-Rad, Hercules, CA, U.S.) and normalized to tubulin levels. These
results are representative of three independently performed experi-
ments.
Figure 2. Ubiquitination of frataxin. Frataxin was immunoprecipitated
from Calu-6 cells extracts, co-transfected with His-frataxin and HA-Ub,
and incubated with 10 μM MG132 for 18 h. Immunoprecipitates were
analyzed by Western blotting with anti-Ub antibody. These results are
representative of three independently performed experiments.
Figure 3. Analysis of the interaction between frataxin and Ub. Western
blotting of GST pull-down experiments. Lysates from Calu-6 cells
treated with MG132 for 18 h, overexpressing His-frataxin or His-
K147R, were pulled down with GST-monoUb or GST (control) as
indicated. The eluted proteins were then immunoblotted with
antibodies against the His epitope. These results are representative
of three independently performed experiments.
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the mutant His-K147R, thereby conﬁrming that K147 is essential
for binding with Ub. The absence of a signal for frataxin in the
pull-down preparation of GST conﬁrmed the speciﬁcity of the
assay.
Structural Model of the Frataxin-K147/Ub Complex. A
computational model of the frataxin/Ub complex was constructed
considering the formation of a covalent isopeptide bond between
the carboxyl group of the C-terminal G76 of Ub and the ε-NH2
group of frataxin K147 with the help of the HADDOCK algorithm.21
The coordinates for the mature human frataxin (residues 90−208)
and Ub were taken from the current crystal structures23,24 without
modiﬁcations. The residues interacting across the frataxin-K147/Ub
complex interface were predicted by two interface prediction
programs, WHISCY25 and ProMate,26 which generate the
ambiguous interaction restraints (AIRs) (Table 1).
Prediction programs identiﬁed L8, I44, G47, and V70 as Ub active
residues. Interestingly, they coincide with the residues known
to form the hydrophobic patch involved in most of the
monoUb/Ub-binding proteins interactions.27,28 The predicted
frataxin active residues V144, Q148, P150, N151, W155, S157, P159,
G162, P163, R165, Y175, located on the external surface of the
β-sheet, match the amino acids highly conserved in all eukaryote
and prokaryote sequences of frataxin (Table 1). The majority of
these residues have no charge, making a ﬂat and nearly neutral
surface, suitable for mediating protein−protein interactions.
The covalent isopeptide bond between the G76 COOH group of
Ub and the ε-NH2 group of K
147 was introduced using unam-
biguous distance restraints based on typical interatomic distances for
a peptide bond in crystal structures, as described previously.22
HADDOCK generated 200 structures, which were then subjected
to clustering. Figure 4 shows a plot of the intermolecular energy,
Einter, of the 200 complex structures as a function of their backbone
root-mean-square deviation (rmsd) from the lowest energy
structure. After analysis, two clusters were obtained. Their statistical
results are summarized in Table 2.
Cluster 1 of frataxin-K147/Ub complex, containing 60 members,
had the best average Einter (−281.9 ± 103.1 kcal/mol). Likewise,
all cluster evaluation parameters showed a signiﬁcantly better
performance of the best-scoring cluster 1 versus cluster 2. For
example, structures from the best-scoring cluster 1 showed the
largest buried surface area (BSA) at the interface (1325 ± 94.8 Å),
suggesting that solutions of the best-scoring cluster present
sensible models for the Ub/frataxin interaction. Accordingly, the
ﬁve lowest-energy structures of this cluster were selected for
further analysis. As depicted in Figure 5, the structure of the
complex is rather well-deﬁned, with a backbone rmsd on inter-
face of 0.51 ± 0.16 Å, and of good quality, with more than 96%
of the residues in the most favored permitted regions of the
Ramachandran plot (see Experimental Section).
A large number of intermolecular hydrophobic contacts were
identiﬁed, together with a few H-bonds and salt bridges, the
major one being between Ub R74 and frataxin D92. The W155
side chain of frataxin, which points toward the center of the
interacting surface of Ub, is in close contact with the Ub L8,
V70, and L71 side chains. Moreover, the frataxin G141 α-H makes
intimate contact with Ub G47. Contribution to the stability of
the complex also comes from the hydrophobic interactions
between P163 and V144 of frataxin and I44, L8, and V70 of Ub.
The three highly conserved frataxin residues W155, P163, and
V144 seem to form a “trident” that anchors the frataxin domain
to the hydrophobic patch of Ub, including L8, I44, G47, and V70
residues (Figure 6). Notably, frataxin residue W155 and
surrounding residues were shown to contribute to binding
interactions with partner proteins and also to be important for
frataxin function in Fe−S cluster biosynthesis.29−32
In Silico Screening of the Open NCI Library on Frataxin.
With the goal of preventing frataxin/Ub association, we went
on to search for small molecules capable of directly targeting
the frataxin region that binds Ub. A multistep structure-based
virtual screening of more than 65 000 leadlike compounds
obtained from the NCI Open Database33 was carried out. This
is a large public database (260 071 compounds) from which
sample compounds can be obtained through the NCI/
Developmental Therapeutics Program. In order to focus the
virtual screening on compounds suitable for further develop-
ment, we selected a subset of leadlike compounds (referred in
this work as the NCI leadlike set).34,35 The selection was made
based on properties and functional groups using the FILTER
Table 1. List of Active and Passive Residues Used in the
Deﬁnition of the AIRs for Docking of Frataxin and Ub
Frataxin (1EKG Chain A)
active residuesa V144, Q148, P150, N151, W155, S157, P159, G162, P163,
R165, Y175
passive residuesa E92, V131, T133, G141, T142, K152, S160, S161, D167, S176, H177,
D178, G179, V180
Ub (1Q0W Chain B)
active residuesa L8, I44, G47, V70
passive residuesa L71, R72, R74




O−NZ 2.25 ± 0.05
C−NZ 1.35 ± 0.05
C−CE 2.45 ± 0.05
CA−NZ 2.45 ± 0.05
aThe active and passive residues for the both protein partners were
calculated by WHISCY Web server. Active residues are residues
predicted to be involved in the interaction, and passive residues are
their surface neighbors. bUb and frataxin are connected via an
isopeptide bond between the carbonyl C of G76 and the NZ atom of
K147 (see Experimental Section).
Figure 4. Intermolecular energies versus backbone rmsd at the
interface from the lowest energy structure for the frataxin-K147/Ub
complex. Values for the single conformations (open circles) and
cluster averages (ﬁlled red circles) are shown. The intermolecular
energy corresponds to the sum of AIR, van der Waals, and electrostatic
energy terms. Nonbonded energies were calculated according to OPLS
parameters, using a 8.5 Å cutoﬀ. Clustering was based on the pairwise
backbone rmsd, using a 2.0 Å cutoﬀ.
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program36 that reduced the initial NCI database to a subset of
65 375 compounds. After selection of leadlike compounds, a
fast docking protocol was employed to further reﬁne the NCI
leadlike set. The general workﬂow of the multistep docking
approach implemented in this work is presented in Figure 7.
Structure-based screening was conducted using two docking
programs, GLIDE37 and AUTODOCK.38 Consensus hits were
selected and tested experimentally. Details of the workﬂow,
screening compound numbers, and ﬁlters used for the virtual
screening are reported in the Experimental Section.
In total, 25 consensus compounds with favorable docking
scores were identiﬁed, and of these, 13 were selected for
experimental testing based on 3D visualization and assessment in
the frataxin/Ub interaction area, including the ﬁt to the binding
site shape, ligand conformation, and ability to form H-bonds with
surrounding residues. The chemical structures of the selected hits
are shown in Figure 8, while their docking scores and leadlike
properties are available as Supporting Information.
The 13 compounds were tested for their ability to prevent the
frataxin ubiquitination. To this aim, Calu-6 cells were transiently
transfected with His-frataxin. At 24 h after the transfection,
untransfected and transfected cells were treated with either 10 μM
MG132 for 18 h or 100 μM of each selected molecule for 72 h.
Untreated and treated cells were then harvested, and protein
extracts were subjected to Western blotting analysis. All solutions
were carefully monitored to avoid artifacts due to precipitation or
agglomeration of compounds. Under assay conditions, aggregation



















cluster 1 [60] 1.14 ± 0.2 −281.9 ± 103.1 −57.3 ± 5.9 −256.6 ± 51.5 34.74 ± 6.7 0.02 ± 0.01 34.72 ± 6.7 1325 ± 94.8
cluster 2 [58] 2.13 ± 0.1 −236.7 ± 70.0 −20.0 ± 6.8 −251.7 ± 31.9 38.07 ± 5.6 0.04 ± 0.02 38.03 ± 5.6 1285 ± 86.5
aClusters are sorted according to average intermolecular energy. bSorting of the generated structures for frataxin-K147/Ub complex into clusters. The
corresponding cluster size is indicated in brackets. cAverage rmsd and standard deviation from the lowest energy structure of all calculated structures.
dIntermolecular energy: sum of the van der Waals and electrostatic energies. eNonbonded energies were calculated with the OPLS parameters using
a 8 Å cutoﬀ. fRestraint energy: sum of unambiguous and ambiguous energies. gUnambiguous energy accounts for isopeptide-bond-related restraints.
hAmbiguous energy accounts for restraints associated with interdomain contacts between the hydrophobic patch on Ub and the higly conserved
residues on frataxin. iTotal BSA: sum of the BSA for both frataxin and Ub subunities.
Figure 5. Ensemble of the ﬁve lowest-energy structures of the lowest-
energy cluster of the frataxin-K147/Ub complex. On the right side, the
structures are viewed 90° from the orientation of those on the left side.
Frataxin is shown in red and Ub in blue. Secondary structure elements
are indicated. The ﬁgure was generated with Pymol (Delano Scientiﬁc
LLC).
Figure 6. Frataxin/Ub interaction. (a) Surface representation of the frataxin-K147/Ub complex. Frataxin and Ub are shown in semitransparent
surfaces (red and blue, respectively) superimposed with their respective ribbon models. (b) Detailed view of the protein interface. Frataxin is shown
in a surface representation superimposed with the ribbon model (red) and a stick model of residues interacting with Ub (white, carbon; blue,
nitrogen; red, oxygen). Ub is shown as a ribbon model (blue) superimposed with a stick model of residues interacting with frataxin (white, carbon;
blue, nitrogen; red, oxygen). The isopeptide linkage between the Ub G76 and frataxin K147 is displayed. The three highly conserved frataxin residues
W155, P163, and V144 (green, carbon) form a “trident” that anchors the frataxin domain to the hydrophobic patch of Ub (L8, I44, G47, and V70 residues).
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of active compounds was not detectable. In addition, none of these
compounds had protein-reactive groups. Among the tested
compounds, the (±)-6-((2,3-dimethoxyphenyl)(4-morpholinyl)-
methyl)-1,3-benzodioxol-5-ol ((±)-11) was found to be the most
eﬀective in preventing the frataxin ubiquitination. Since compound
11 was tested as a racemic mixture, it was synthesized and resolved
into its enantiomers (+)-11 and (−)-11, which were assayed
individually and compared to the racemate.
Synthesis and Resolution of Racemic Mixture of 11.
Reaction between morpholine (a), 2,3-dimethoxybenzaldehyde
(b), and benzo[d][1,3]dioxol-5-ol (c) resulted in the synthesis
of (±)-11 (Scheme 1). This reaction was studied under two
conditions as follows: pathway A consisting of reﬂux in ethanol
for 72 h; pathway B consisting of solvent-free microwave irradiation
using CEM Discover S class microwave oven at 125 °C for 5 min in
the absence of any catalyst.
Pathway A suﬀers from long reaction times up to several days
and produces modest yields of product (about 47%) with a
moderate enantiomeric excess (57%) for the (+)-isomer. On
the contrary, the microwave-assisted solvent-free reaction
(pathway B), a most eﬃcient synthetic method in terms of
energy and time consumption, furnishes better yields of the
product (87%), with an equimolar presence of the two (+)- and
(−)-enantiomers.
On the basis of these results, a hypothetical mechanism of
reaction could be proposed to justify the diﬀerent trend of the
two pathways A and B (Scheme 2). In both synthetic methods,
the secondary amine a attacks the carbonyl group of aldehyde
b, yielding a racemic hemiaminale intermediate H. In pathway
A, the electron poor carbon of H undergoes a SN2 displacement
by the carbon α to the phenol OH group of c to give a
transition state with the geometry of a pentagonal bipyramid,
probably stabilized by an intramolecular H-bond between the
nitrogen of the morpholine and the phenol OH group. The
formation of this six-membered H-bond could determinate a
transient intermediate responsible for the excess of the
(+)-isomer of 11.
Under microwave irradiation (pathway B), a trigonal planar
carbocation intermediate can be formed starting from H. The
attack of phenol c, occurring on either face of the carbocation,
yields the racemic mixture of 11.
The most practical method for the resolution of racemic
amines is the preparation of diastereomeric salts with an
optically active acid and then separation via crystallization.39 The
resolution of (±)-11 was accomplished through the sequential
use of L- and D-tartaric acid (Scheme 3). When (±)-11 and
L-(+)-tartaric acid were used in a 1:0.5 ratio, (−)-11 and (+)-11
were isolated in 30% and 37% yields with >99% and 97% ee,
respectively. In an optimized protocol, (±)-11 and L-(+)-tartaric
acid (0.5 equiv) were mixed in ethanol and stirred overnight. The
solid tartrate salt was separated from the unreacted 11 through
extraction with ether. Subsequent recrystallization of the salt from
ethanol and basiﬁcation gave (−)-11. The (+)-enantiomer was
obtained from the mother liquor by similar treatment with
D-(−)-tartaric acid. Both enantiomers were obtained in good yields
and high enantiomeric purity after a single crystallization of the
corresponding tartrate salts. The enantiomeric purity of both
enantiomers was determined by chiral HPLC.
(+)-11 Promotes the Accumulation of Frataxin
Precursor in Calu-6 Cells. Figure 9 shows the eﬀect of
50 μM (±)-11, (+)-11, and (−)-11 on the accumulation of
precursor and mature frataxin in Calu-6 cells. In comparison
with the racemate (±)-11, the isomer (+)-11 indirectly induced
a larger increase in the cellular concentration of mature frataxin
by signiﬁcantly restoring the endogenous level of frataxin precursor
(Figure 9a). In contrast, (−)-11 displayed no increase in the
cellular concentration of frataxin, indicating a ﬁne degree of
selectivity in the binding site due to chiral geometry.
To verify that the increase of mature frataxin levels in cells is
indeed due to the capacity of (+)-11 to prevent the conjugation
of Ub molecule with frataxin precursor, Calu-6 cells were
transiently transfected with the plasmid encoding His-frataxin,
and 24 h after the transfection, cells were treated with either
10 μM MG132 or 10 μM MG132 and 50 μM (+)-11. His-
frataxin was then analyzed for its ability to bind to immobilized
GST-monoUb. The puriﬁed GST and GST-monoUb were
immobilized using GSH-Sepharose beads and incubated with
the cell lysates treated or not with (+)-11. After the binding, the
eluted proteins were analyzed by Western blotting with
antibodies anti-His. Figure 9b shows that the signal for frataxin
was present in the pull-down sample of untreated cells and absent
in that of (+)-11 treated cells, indicating that this compound is
able to prevent the conjugation of Ub to frataxin precursor.
Experiments conducted in Calu-6 cells with increasing compound
concentrations showed a dose-dependent behavior of (+)-11 in
preventing the ubiquitination of frataxin (Figure S1 of Supporting
Information). The IC50 for inhibition of frataxin ubiquitination was
determined to be 45 μM. Cell viability was not impaired by (+)-11
concentrations up to 100 μM.
Binding Aﬃnity of Compound (+)-11 to Frataxin. To
investigate the binding aﬃnity of (+)-11 with frataxin, we
employed an UF-LC/MS based ligand-binding assay.40,41 Initially
in the binding assay experiments compound (+)-11 (1 μM) was
incubated at 25 and 37 °C with 1 μM for His-frataxin recombinant
protein in a total volume of 200 μL of assay buﬀer. After the
Figure 7. Flow chart of the multistep virtual screening strategy
implemented in this work.
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incubation, the unbound compound from the ligand−protein
complex was removed by washing with assay buﬀer. Then the
ligand was dissociated from the complex and analyzed by LC/MS.
In the positive electrospray mass spectrum, the protonated
molecule of compound (+)-11 was detected at m/z 374.1598
[M + H]+. Figure 10 shows the LC/MS analysis of an ultraﬁltrate
obtained from the incubation of test compound (+)-11 with
Figure 8. Chemical structures of compounds yielded by the multistep docking approach and tested experimentally.
Scheme 1. Synthesis of Compound (±)-11
Scheme 2
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frataxin protein at 25 °C. The peak area of compound (+)-11 was
enhanced 3.70-fold in the chromatogram corresponding to the
incubation with active frataxin compared to the control experiment
carried out with denatured protein, which showed that compound
(+)-11 possesses speciﬁc binding aﬃnity to frataxin. The peak area
enhancement of (+)-11 was 3.32-fold compared to control
experiment when incubated at human body temperature of 37 °C.
The relative binding aﬃnity was ascertained by calculating the
ratio between the average peak area of compound incubated with
active protein and the average peak area of compound incubated
with denatured protein. Our results show that (+)-11 has speciﬁc
binding aﬃnity to frataxin. We attempted to investigate entropy
and enthalpy changes by isothermal titration calorimetry, but these
experiments unfortunately did not yield interpretable data (data
not shown).
Although the absolute conﬁguration of (+)-11 is not known
at the moment, we assume that it has R conﬁguration, since
docking calculations predicted the R enantiomer to bind more
favorably to frataxin than the corresponding S enantiomer. We
are currently attempting to crystallize the (+)-11/frataxin
complex. Figure 11 illustrates a model of the (R)-11/frataxin
complex as predicted by GLIDE. According to this model,
residues V144, N146, W155, S157, G162, P163, and R165 form the
binding pocket of (R)-11, and a network of H-bonds is predicted
between the ligand and the side chains of N146, S157, and R165. In
particular, the meta methoxy oxygen of the phenyl ring of 11
forms bidentate H-bonds to the R165 side chain, while the OH
oxygen of the benzodioxole system accepts a H-bond from the
NH carboxamide of the N146 side chain. The morpholine oxygen
atom is engaged in a H-bond with the S157 OH group. Further-
more, the ligand makes hydrophobic contacts with residues W155,
P163, and V144. Speciﬁcally, the dimethoxyphenyl ring and the
benzodioxole aromatic ring of the ligand are oriented in such a
way to establish parallel-displaced and T-shaped π−π stacking
interactions with the W155 side chain.
Scaﬀold Searching and SAR Development. Hierarchical
screening is an eﬃcient strategy allowing an initial broad search
over a chemically and pharmacologically diverse set of compounds,
followed by a focused search over a much larger database to ﬁnd
molecules related to potential lead compounds. The most
promising compound 11 was selected for scaﬀold-searching and
Scheme 3. Resolution of (+)-11 and (−)-11 Enantiomers
Figure 9. Eﬀect of (±)-11, (+)-11, and (−)-11 on human frataxin
precursor and frataxin accumulation. (a) Western blot analysis with the
indicated antibodies of protein extracts from Calu-6 cells transiently
transfected with His-frataxin untreated and treated with 50 μM
(±)-11, (+)-11, and (−)-11 for 3 days or 10 μMMG132 for 18 h. The
levels of proteins were quantiﬁed by PhosphorImager (Bio-Rad,
Hercules, CA, U.S.) and normalized to tubulin levels. (b) Western
blotting of GST pull-down experiments. Lysates from the same cells
were pulled down with GST-monoUb or GST (control) as indicated.
The eluted proteins were then immunoblotted with antibodies against
the His epitope. These results are representative of three
independently performed experiments.
Figure 10. Ultraﬁltration LC/MS screening of compound (+)-11
incubated with 1 μM His-frataxin recombinant protein. Compound
(+)-11 was tested at 1 μM. The solid line represents the experiment
using active frataxin protein, and the dotted line corresponds to the
control incubation using denatured frataxin protein.
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SAR expansion studies. Substructure and similarity follow-up
searches over the full NCI database resulted in 38 compounds
matching the scaﬀold, which were docked to the frataxin Ub-
binding site and ranked according to the predicted GLIDE XP/
AUTODOCK consensus scoring. The top 12 compounds with
the lowest scoring value for frataxin Ub-binding site were selected
for experimental testing (Table 3). It was gratifying that they all
showed a dose-dependent behavior in preventing the conjugation
of Ub molecule to the precursor frataxin (Supporting Information
Figure S1), conﬁrming the viability of the core structure from 11.
Values of experimental IC50 (μM) for inhibition of frataxin
ubiquitination were obtained as described in the Experimental
Section. As previously, aggregation eﬀects were excluded, and
compound identity and purity were conﬁrmed by elemental
analysis and 1H NMR (see Supporting Information).
As can be seen from data shown in Table 3, replacement of
the morpholine ring with a piperidine (compound 23) or
pyrrolidine ring (compound 24) led to a considerable reduction
of activity. This is due to the loss of the H-bond between the
morpholine oxygen and the OH group of S157. We observed a
nearly 2-fold increase in inhibitory activity (from 45 to 20 μM)
when the methoxy substituents were in meta and para positions
of the phenyl ring (compound 15), with a slight preference for
the meta over the para position in this series (cf. compounds 18
and 14). Compounds 14, 16, and 17, lacking the meta methoxy
substituent on the aromatic ring, were less potent than
compound 11. Docking of the two most active compounds
15 and 18 into the frataxin Ub-binding domain indicated that
the oxygen atoms of the meta and para methoxy groups are
optimally oriented to form two stable H-bonds to the R165 side
chain (Supporting Information Figure S2).
We also observed that halogens (compounds 20 and 21) and
basic (compound 22) substituents at the para position of the
phenyl ring led to a nearly 1.5-fold decrease in activity over
compound 11. Finally, replacement of substituted phenyl ring
with a benzodioxole system led to a drastic reduction in activity.
From a visual inspection of compound 25 complexed to Ub-
binding domain of frataxin, it seems clear that the presence of a
second benzodioxole ring in the molecule increases the steric
hindrance inside the binding cavity and changes the optimal
binding mode of the ligand, thus decreasing the relative stability
of the complex.
■ CONCLUSION
Here we describe our eﬀorts in identifying novel small-molecule
inhibitors that perturb conjugation of Ub onto frataxin. To this
aim, we veriﬁed that treatment of Calu-6 cells with proteasome
Figure 11. Binding mode of compound (R)-11 (yellow) into the
frataxin Ub-binding domain shown as a surface representation
superimposed with the ribbon model (red). Only amino acids located
within 3.5 Å of the ligand are shown and labeled. The highly conserved
residues W155, P163, and V144 involved in Ub binding are displayed in
green. H-bonds are indicated by dashed black lines.
Table 3. Structure and Activity of Compound 11 Scaﬀold Search Hits
compd NSC no. R1 R2 R3 R4 R5 X consensus score QP log P
a IC50 (μM)
b
14 364724 H H OCH3 H H O −11.41 1.91 65 ± 9.0
15 368252 H OCH3 OCH3 H H O −11.60 2.08 20 ± 4.0
16 381577 OCH3 H OCH3 H OCH3 O −9.28 2.31 53 ± 4.0
17 370277 OCH3 H OCH3 H H O −10.54 2.30 44 ± 9.0
18 368256 OH OCH3 H H H O −10.95 1.70 29 ± 4.0
19 667921 OH H H H H O −10.41 1.63 80 ± 9.0
20 368275 H H Cl H H O −10.94 2.55 68 ± 9.0
21 368277 H H F H H O −10.67 2.29 67 ± 5.0
22 368269 H H N(CH3)2 H H O −10.14 2.42 81 ± 9.0
23 368274 H H OCH3 H H C −10.38 3.10 82 ± 5.0
24 370281 −10.06 2.96 97 ± 12.0
25 368248 −10.12 1.64 70 ± 9.5
(+)-11 381576 OCH3 OCH3 H H H O −11.13 2.41 45 ± 6.0
aPredicted octanol/water partition coeﬃcient using the QikProp 3.4 program [50]; range of recommended values (−2.0)-(+6.5). bIC50 values are
the means ± SEM of a series separate assays, each performed in triplicate.
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inhibitors (MG132 and bortezomib) led to a signiﬁcant
accumulation of frataxin precursor and, indirectly, of its mature
form, thereby conﬁrming the role of the UPS in the
degradation pathway of frataxin. Site-directed mutagenesis
experiments showed that K147/R mutant of frataxin completely
failed to conjugate Ub, suggesting that this lysine residue is its
target site for Ub conjugation. With the help of the protein−
protein docking program HADDOCK, we built a computa-
tional model of the frataxin-K147/Ub complex. A small molecule
(compound (±)-11) targeting the Ub-binding domain of
frataxin was identiﬁed by a multistep structure-based virtual
screening. This chiral compound was synthesized and resolved
in its optical isomers. (+)-11 was the active isomer capable of
blocking the frataxin ubiquitination and of promoting the
accumulation of both precursor and mature frataxin species in
Calu-6 cells. The binding aﬃnity of (+)-11 for frataxin was
investigated through the UF-LC/MS based ligand-binding
assay. The peak area of the ligand in the chromatogram
corresponding to incubation with active frataxin increased by
3.70-fold compared to the chromatogram of test compound
incubated with denatured protein, thus revealing the existence
of a speciﬁc interaction between (+)-11 and frataxin. A docking
model elucidating the putative interactions between compound
11 and frataxin Ub-binding site is proposed. On the basis of this
model, it can be hypothesized that compound 11 could mask the
residues required for Ub interaction or mask a putative sequence
containing some form of signal that is recognized by Ub
machinery. Substructure and similarity follow-up searches on the
most active hit compound 11 yielded a series of morpholino
analogues with a key meta and para methoxy substituted phenyl
ring that possessed activity in the micromolar range.
In conclusion, by combining theoretical and experimental
approaches, we identiﬁed a small molecule that disrupts the
frataxin/Ub interaction determining a half-life increase of cellular
frataxin. This ﬁnding is very signiﬁcant because the increment in
the residual levels of frataxin could open therapeutic perspectives
for the FRDA disease.
■ EXPERIMENTAL SECTION
Interface Prediction. The X-ray coordinate ﬁles of human frataxin
(PDB code 1EKG, chain A)23 and Ub (PDB code 1UBQ)24 were
downloaded from the PDB,42 while the multiple sequence alignments
were taken from the HSSP database (ftp://ftp.cmbi.kun.nl/pub/
molbio/data/hssp).43 The ﬁrst aligned sequence in the HSSP ﬁle was
taken as master sequence. WHISCY25 and ProMate26 were used for inter-
face predictions and combined for consensus scoring using WHISCY-
MATE.25 Multiple sequence alignments were used for WHISCY
prediction: if there was any disagreement between structure and master
sequences about a residue identity, the residue of the master sequence was
used. The parts of a structure that were not present in the alignment were
not predicted and ignored in the evaluation. ProMate predictions were
obtained making use of the Web interface of ProMate (http://bioinfo.
weizmann.ac.il/promate/promate.html) using default settings. For WHIS-
CYMATE, a residue was predicted if its ProMate score was higher than or
equal to 98.520, its WHISCY score higher than or equal to 0.371, or its
ProMate and WHISCY scores were both higher than or equal to 55.420
and 0.107, respectively. Interface predictions were used to generate AIRs as
discussed before:25 predicted residues were designated active residues and
their surface neighbors passive residues (Table 1).
Docking for the Frataxin-K147/Ub Complex. A structural model
of frataxin-K147/Ub complex was obtained following a WHISCY-
HADDOCK docking approach.21,22 The crystal structures of the
human frataxin23 and Ub24 were used for mapping the interfaces and
docking the structures. The restraints that were used in this study are
listed in Table 1. Ub and frataxin were linked to one another via a
G76-K147 isopeptide bond. To account for the possible close contact
between the hydrophobic patch on Ub (residues L8, I44, G47, and V70)
and the highly conserved residues on the frataxin external surface, we
incorporated AIRs where active and passive residues on both Ub and
frataxin were deﬁned exploiting the interface prediction WHISCY
program.25 The G76-K147 isopeptide bond was modeled by including a
set of distance restraints based on typical interatomic distances for a
peptide bond in crystal structures, as described previously.22 Backbone
and side chain ﬂexibility was also included to account for a possible
conformational rearrangement that could occur at the interface
between both Ub and frataxin moieties (Table 1). Flexible segments
were deﬁned as stretches of active and passive residues plus one
sequential neighbor. The docking calculations were performed with
the standard HADDOCK protocol as described by Dominguez et al.21
For each run, 1000 rigid-body docking solutions were ﬁrst generated
by energy minimization. The driving force for the docking at this stage
comes mainly from the AIRs and from van der Waals and electrostatic
energy terms once the structures are within the nonbonded cutoﬀ (8.5 Å).
The 200 best solutions according to the AIR restraint energy (as deﬁned
in ref 21) were subjected to semiﬂexible simulated annealing in torsion
angle space followed by a ﬁnal reﬁnement in explicit water.44 During the
simulated annealing and the water reﬁnement, the amino acids at
the interface (side chains and backbone) are allowed to move to optimize
the interface packing. The nonbonded energies were calculated with the
OPLS parameters45 using a 8.5 Å distance cutoﬀ. A dielectric constant of
10 was chosen for the vacuum stages of the docking protocol (rigid-body
and semiﬂexible reﬁnement).
The resulting structures were ﬁnally subjected to a ﬁnal reﬁnement
in explicit water, clustered using a 2.0 Å backbone rmsd cutoﬀ
criterion, and sorted according to the intermolecular energy (sum of
the van der Waals, electrostatic, and AIRs energy). BSA was calculated
by taking the diﬀerence between the sum of the solvent-accessible
surface area for each partner separately and the solvent-accessible
area of the complex. The solvent-accessible area was calculated using
a 1.4 Å water probe radius. The ﬁve best structures of the lowest
energy cluster of each HADDOCK run were analyzed in terms of
intermolecular contacts, and an average structure was calculated by
superimposing the structures on the backbone atoms of the ﬂexible
segments. The Ramachandran plot of the generated model shows
71.7% of the residues in the most favored regions, 24.9% in the
additional allowed regions, 1.1% in the generously allowed region, and
2.3% in the disallowed regions. Intermolecular contacts (H-bonds and
nonbonded contacts) were analyzed with DIMPLOT, which is part of
the LIGPLOT software, using the default settings (3.9 Å heavy-atoms
distance cutoﬀ for nonbonded contacts; 2.7 and 3.35 Å proton−
acceptor and donor−acceptor distance cut-oﬀs, respectively, with
minimum 90° angles [D−H−A, H−A−AA, D−A−AA] for hydrogen
bonds).46
Protein Preparation. The X-ray coordinates of human frataxin23
were prepared using the Protein Preparation Wizard implemented in
the Schrodinger package using default options: bond orders were
assigned, hydrogens were added, and all water molecules were deleted.
Hydrogens were then optimized using the exhaustive sampling option, and
the protein was minimized to an rmsd limit from the starting structure of
0.3 Å using the Impref module of Impact with the OPLS_2005 force ﬁeld.
Database: Leadlike Selection and Preparation. The NCI Open
Database33 with 260 071 compounds was obtained from ZINC.47 The
compound database was processed with FILTER,36 version 2.0.1, to
select a subset of leadlike compounds. We used the default parameters
in the leadlike ﬁlter without further modiﬁcations. The resulting
database contained 65 375 compounds. For docking, diﬀerent
protonation states and tautomers were generated with the GLIDE
module LIGPREP. This yielded a total of 90 653 structures.
Docking with GLIDE and AUTODOCK. We employed the high-
throughput virtual screening (HTVS) docking mode in GLIDE,37
version 5.7, for a rapid structure-based ﬁltering of the NCI leadlike set.
This data set was docked onto the putative frataxin Ub-binding
domain. The grid-enclosing box, which must contain the center of
each ligand docked, was centered on the W155 side chain and deﬁned
to enclose residues located within 14 Å from W155, while the outer box,
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in which all parts of the ligand must bind, was 35 Å in each direction. A
van der Waals radius scaling factor of 0.80 for atoms with a partial
atomic charge (absolute value) less than 0.15 was used in order to
soften the potential for nonpolar parts of theprotein. Next, a ﬂexible
docking with default parameters was employed for virtual screening.
The general workﬂow of the multistep docking approach implemented
is depicted in Figure 7. The top-ranked compounds with GLIDE
HTVS (4532 unique molecules) were docked ﬂexibly in a stepwise
manner with GLIDE Standard Precision (SP) and Extra Precision
(XP). We employed default parameters with the same receptor grids
used with GLIDE HTVS. Selected compounds docked with GLIDE
XP (226 unique molecules) were also docked with AUTODOCK,38
version 4.2. We used the same grid maps (centered on W155 residue)
and default docking parameters. The only modiﬁcation was the
number of docking runs that was set to 10 for faster virtual screening.
A consensus score was generated by combining both the
AUTODOCK binding energy and the XP GLIDE score energy in
order to increase conﬁdence in the resulting energy score. High
ranking poses by two diﬀerent scoring functions represent, by
construction, a more reliable prediction than any of the constituent
scoring functions alone. In practice, consensus scoring has been
generally found to improve virtual screening performance dramatically
with respect to the individual scoring functions.48,49 Out of the ﬁnal
50 compounds identiﬁed from the multistep docking approach, 13
(Figure 8) were selected for experimental testing. The program
QikProp,50 version 3.4, was used for calculating the ADME proprieties.
Scaﬀold Search. An online search utility provided by the NCI
(http://129.43.27.140/ncidb2/)51 was used to search the entire NCI
database for compounds similar to compound 11. Two methods were
used to judge compound similarity: search on the basis of substructure
by SMILES string (http://daylight.com) and similarity by Tanimoto
coeﬃcient,52 with a cutoﬀ of 0.85.53 From these searches, selected
compound structures were docked to the frataxin Ub-binding site and
ranked according to predicted GLIDE XP/AUTODOCK consensus
scoring. Compounds with the lowest scoring value were requested and
assayed for eﬀect on frataxin ubiquitination.
General Procedures. Reagents, starting material, and solvents
were purchased from commercial suppliers and were used as received.
Analytical TLC was performed on a 0.25 mm layer of silica gel 60
F254 from Merck, and preparative TLC was performed on 20 ×
20 cm2 glass plates coated with a 2 mm layer of silica gel PF254 from
Merck. Silica gel 60 (300−400 mesh), Merck, was used for ﬂash
chromatography. Melting points were taken on a Koﬂer apparatus and
are uncorrected. Optical rotations were determined with a Perkin-
Elmer 241 MC polarimeter. 1H NMR spectra were recorded with a
Bruker 500 spectrometer. Chemical shifts are reported in δ relative to
internal Me4Si, and J values are reported in Hz. Electrospray mass
spectra were recorded using a WATERS Z-Q mass spectrometer
equipped with an electrospray ionization (ESI) probe operating in
positive or negative ion mode. CEM Discover S class microwave
reactor was used for the microwave-assisted reactions.
Synthesis of 6-((2,3-Dimethoxyphenyl)(4-morpholinyl)-
methyl)-1,3-benzodioxol-5-ol ((±)-11). Morpholine (a), 2,3-
dimethoxybenzaldehyde (b), and benzo[d][1,3]dioxol-5-ol (c) were
combined, and two reaction conditions were employed.
Pathway A. a (870 μL, 10 mmol), b (1.66 g, 10 mmol), and c (1.38
g, 10 mmol) were dissolved in ethanol (40 mL) and reﬂuxed for 72 h.
After the reaction proceeded for the stated period of time, a mass of
colorless crystals separated. These were collected and recrystallized
from acetone/methanol to give 1.75 g of 11 (yield 47%). Mp (°C):
141−142. 1H NMR (500 MHz, CHCl3-d1) δ 7.32−762 (m, 3H), 6.43
(s, 1H), 6.38 (s, 1H), 5.82 (d, J = 1.0 Hz, 1H), 5.78 (d, J = 1.0 Hz,
1H), 4.96 (s, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.70 (m, 4H), 2.52 (m,
4H). ESI-MS: 374 (M + H)+. Anal. Calcd for C20H23NO6: C 64.33, H
6.21, N 3.75. Found: C 64.41, H 6.26, N 3.80.
Pathway B. A mixture of a (87 μL, 1 mmol), b (166 mg, 1 mmol),
and c (138 mg, 1 mmol) was mixed in a 50 mL ﬂask and irradiated in a
CEM Discover S class microwave oven at 125 °C for 10 min in the
absence of any catalyst. The progress of the reaction was monitored
with TLC. After cooling, the mixture was extracted with chloroform.
Evaporation of the solvent under reduced pressure gave the crude
product, which was recrystallized from acetone/methanol to give 324
mg of 11 (yield 87%).
Resolution of (±)-11. To a solution of L-(+)-tartaric acid (0.15 g,
1.0 mmol) in ethanol (3 mL) was added a solution of (±)-11 (1.5 g,
4 mmol) in ethanol (15 mL), and the resulting mixture was stirred
overnight at room temperature. Ethanol was then removed on a rotary
evaporator at 40 °C. To the residue, diethyl ether (10 mL) was added,
and the mixture was stirred for 1 h. Filtration of the reaction mixture
provided the tartrate salt, which was recrystallized from ethanol
(10 mL) to obtain white crystals. This solid was treated with aqueous
NaOH solution, then extracted with CH2Cl2, dried over Na2SO4 and
the solvent removed under reduced pressure to aﬀord a white powder
0.21 g (yield 30%), mp 141−142 °C. The enantiomeric purity was
determined by chiral HPLC (Daicel Chiralcel OD-H, hexane/
isopropanol = 97.5:2.5, ﬂow rate 1.0 mL/min) and was found to be
>99%, [α]D
25 −171.4 (c 0.42, CH2Cl2). The second isomer of 11 was
isolated from the mother liquor and treated with D-(−)-tartaric acid in
ethanol as described above, providing the corresponding (+)-enan-
tiomer, 0.27 g (yield 37%); mp 139−140 °C; [α]D25 +151.2 (c 0.39,
CH2Cl2). The enantiomeric purity was determined by chiral HPLC
and was found to be 97%.
Cell Cultures, Constructs, and Transfections. The human lung
carcinoma Calu-6 cell line (ATCC, HTB 56; ICLC, HTL97003) was
cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) with
Glutamax (Invitrogen, Carlsbad, California) supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 50 U/mL penicillin−
streptomycin, and 0.1 mM nonessential amino acids. Plasmids were
transfected in Calu-6 cell line by using LIPOTAXI (Agilent) according
to the manufacturer’s instructions. Transfection eﬃciency was assessed
by co-transfecting a GFP-expressing vector and normalizing RNA levels
against GFP mRNA levels (data not shown). Where indicated, 24 h after
transfection, cells were treated either with 10 μM proteosome inhibitors
(MG132, bortezomib) for 18 h or with 100 μM of each of the 13
molecules selected by the multistep docking approach for 72 h. Then
proteins were extracted and analyzed by Western blotting.
DNA Constructs and Production of Recombinant Proteins.
The cDNA of frataxin was obtained by RT-PCR from cells using the
primers forward 5′-TATGTGGACTCTCGGGCG-3′ and reverse 5′-
TAGCATCTTTTCCGGAATAGG-3′ and cloned into the eukaryotic
expression vector pcDNA3.1 H/Myc C (Invitrogen) and prokaryotic
expression vector pRSET-A (Invitrogen). The cDNA of mutated
frataxin containing R147 for K147 was generated using the QuikChange
Lightning site-directed mutagenesis kit (Stratagene, catalog no.
210518) using the primers forward 5′-ATGTGATCAACAGG-
CAGACGCCAAACAAG-3′ and reverse 5′-CTTGTTTG-
GCGTCTGCCTGTTGATCACA-3′ and cloned into the prokaryotic
expression vector pRSET-A to obtain the His-K147R construct. The
cDNA of human Ub (a gift from Dr. V. Colantuoni) was cloned in the
prokaryotic expression vector pGEX4T3 (GE Healthcare, Waukesha, WI).
The recombinant proteins GST-monoubiquitin and GST were expressed
in Escherichia coli and puriﬁed by using glutathione Sepharose 4B beads
according to the manufacturer’s instructions (GE Healthcare). The
recombinant proteins His-frataxin and His-K147R were expressed in E.coli
and puriﬁed by nickel nitrilotriacetic acid (Ni-NTA)−agarose chromatog-
raphy according to the manufacturer’s instructions (Qiagen, Valencia, CA).
Chemicals. All compounds were kindly provided by NCI (http://
dtp.cancer.gov). The identity and purity of the assayed compounds
were independently assessed by elemental analysis and 1H NMR (see
Supporting Information). Proteasome inhibitors MG132 and
bortezomib were from Sigma-Aldrich and Santa Cruz Biotechnology,
respectively.
Immunoprecipitation and Western Blotting. For immunopre-
cipitation assay, an amount of 1.5 mg of cell extracts was incubated
with 20 μL of protein A/G agarose beads coated with 5 μL of antibody
against frataxin (Millipore) at 4 °C for 12 h. The beads were washed
and boiled in the SDS sample buﬀer. The eluted proteins were loaded
on 12% SDS−PAGE and detected by Western blotting. Aliquots of
protein samples (50 μg) were resolved by 15% SDS−gel electro-
phoresis and transferred into nitrocellulose ﬁlters. The membranes
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were blocked in PBS, 0.1% Triton, and 5% dry milk for 2 h and then
challenged with anti-frataxin (Millipore). The proteins were visualized
with enhanced chemiluminescence detection reagent according to the
manufacturer’s instructions (Pierce, Rockford, Illinois).
Ubiquitination Assay and GST Pull-Down. For Ub assay, Calu-
6 cells were transiently transfected with plasmids encoding His-frataxin
or His-K147R. At 24 h after transfection, cells were treated with 10 μM
proteosomal inhibitor MG132 dissolved in DMSO for 18 h or with
50 μM (+)-11 for 3 days and MG132 in the last 18 h. Then cells were
harvested and lysed for 10 min on ice in lysis buﬀer (50 mM HEPES,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton-
X-100, 25 mM NaF, 10 μM ZnCl2, pH 7,5) containing protease
inhibitor 1× (Roche). Cell lysates were then collected and centrifuged
for 15 min at 13000g. An amount of 500 μg of the soluble fraction was
incubated with 5 μg of GST-monoUb or GST coupled to glutathione
Sepharose 4B (Amersham Biosciences, Frieburg, Germany) in pull-
down buﬀer (50 mM Tris-HCl, pH 7.5, 0.4 mM EDTA, 150 mM
NaCl, 10% glicerol, 1% NP-40, 1 mM sodium orthovanadate, 50 mM
NaF, 5 mM DTT, and protease inhibitor mix 1×) for 4 h at 4 °C. After
incubation, the beads were washed three times with lysis buﬀer. Eluted
proteins were loaded on 12% SDS−PAGE and analyzed by
immunoblotting using anti-His antibodies. Band intensities of
ubiquitinated frataxin were quantiﬁed by densitometry scanner analysis
(Bio-Rad, Hercules, CA, U.S.), and relative values are shown as
percentage of control. Each data point represents the mean ± SEM of
at least three independent experiments. The IC50 values were
calculated using a four-parameter logistical model of the graph of
log of dose against percentage of ubiquitinated frataxin values.
UF-LC/MS Based Frataxin Binding Assay. The test compound
(+)-11 (1 μM in 4 μL of DMSO) and 185 μL of assay buﬀer
consisting of 100 mM Tris-HCl (pH 7.5), 50 mM KCl, and 5 mM
MgCl2 were placed into a microcentrifuge tube and incubated for
2 min at 25 °C. The binding assay was initiated by the addition of
1 μMHis-frataxin recombinant protein and incubated further for 60 min
at 25 °C. After incubation the binding mixture was ﬁltered through an
ultramembrane ﬁlter (Microcon YM-10, Millipore, Billerica, MA)
according to the modiﬁed method of Nikolic et al.40 and centrifuged at
13000g for 20 min at 4 °C. The protein−ligand complex was treated
with assay buﬀer (200 μL × 3) and centrifuged at 13000g for 20 min at
4 °C to remove the unbound ligand. The ultramembrane ﬁlter was
then placed into a new microcentrifuge tube, and the protein−ligand
complex was allowed to stand in 200 μL of methanol for 20 min to
dissociate the ligand completely. The content was then centrifuged at
13000g for 20 min at 20 °C. The ultracentrifugate was dried under
nitrogen (NVAP 116 nitrogen evaporator, Organomation Associates,
Inc., Berlin, MA). The sample was reconstituted in 100 μL of 50%
methanol in deionized water (v/v) and analyzed by LC/MS. A control
experiment was carried out in a similar manner with denatured His-
frataxin protein. Prior to the assay, the protein was denatured by
heating at 90 °C for 1 h. The test compound (+)-11 was prepared in
DMSO. The concentration of DMSO in the assay never exceeded 2%
(v/v), a concentration that was found not to inﬂuence the results of
the assay. The binding experiments for compound (+)-11 (1 μM)
against 1 μM His-frataxin protein were carried out at 25 and 37 °C to
evaluate the inﬂuence of temperature. All the binding assays were
performed in duplicate and analyzed twice.
LC/MS Analysis of Compound (+)-11. Analysis of (+)-11 was
carried out using an Agilent (Little Falls, DE) 6520 Accurate-Mass Q-
TOF mass spectrometer equipped with an Agilent 1200 RRLC system.
Chromatographic analysis of (+)-11 was carried out using ZORBAX
Eclipse plus C18 column (2.1 mm × 100 mm, 1.8 μm). The gradient
solvent systems used were solvent A (95% water/5% methanol/0.1%
acetic acid, v/v) and solvent B (0.1% acetic acid in methanol, v/v).
The linear gradient was increased from 50% to 100% B in 5 min. The
mobile phase was maintained with 100% B up to 6 min and then
returned to the initial conditions of 50% B in 7 min. The column was
equilibrated with 50% B for 5 min. The ﬂow rate was 0.2 mL/min, and
the injection volume for all samples was 2 μL. Nitrogen was supplied
as nebulizing and drying gas at ﬂow rates of 30 and 480 L/h,
respectively. The drying gas temperature was 350 °C. The ESI source
was operated with a capillary voltage of 3200 V. The fragmentor
voltage was optimized to 175 eV. The released ligand (2 μL) was
subjected to LC/MS analysis with a ﬂow rate of 0.2 mL/min.
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L-leucinal; NCI, National Cancer Institute; PBS, phosphate
buﬀered saline; PDB, Protein Data Bank; rmsd, root-mean-square
deviation; SDS−PAGE, sodium dodecyl sulfate−polyacrylamide
gel electrophoresis; Ub, ubiquitin; UF-LC/MS, ultraﬁltration
liquid chromatography/mass spectrometry; UPS, ubiquitin
proteasome system
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